Neurodevelopmental Outcome of Newborns with Persistent Pulmonary Hypertension.
Background: Developmental disabilities have been reported in infants with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (INO) or intravenous magnesium sulphate (MgSO4) and/or extracorporeal membrane oxygenation. This paper reports the rate of developmental...
| Publicado en: | Malaysian Journal of Medical Sciences Vol. 18; no. 4; pp. 58 - 63 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Malaysian Journal of Medical Sciences
Oct-Dec2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=69984496&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 69984496 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1394195X YQP jtl: Malaysian Journal of Medical Sciences issn: 1394195X maglogo: N pubinfo: dt: Oct-Dec2011 vid: 18 iid: 4 pid: 23493 pub: Malaysian Journal of Medical Sciences artinfo: ui: 69984496 69984496 104620893 69984496 ppf: 58 ppct: 5 formats: tig: atl: Neurodevelopmental Outcome of Newborns with Persistent Pulmonary Hypertension. aug: au: Rohana, Jaafar Boo, Nem Yun Chandran, Viji Sarvananthan, Rajini affil: Department of Paediatrics, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia sug: subj: Hypertension, Pulmonary Human Development Outcomes Research Human Malaysia Infant Prospective Studies Scales Neuropsychological Tests Magnesium Sulfate Nitric Oxide Developmental Disabilities Equipment and Supplies Data Analysis Software Mann-Whitney U Test Male Female Infant: 1-23 months Male Female ab: Background: Developmental disabilities have been reported in infants with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (INO) or intravenous magnesium sulphate (MgSO4) and/or extracorporeal membrane oxygenation. This paper reports the rate of developmental disabilities at 2 years of age in a cohort of survivors of PPHN treated with INO, MgSO4, or both during the neonatal period. Methods: Sixteen survivors of PPHN were prospectively followed up. These infants were treated with intravenous MgSO4 and/or INO during the neonatal period. Neurodevelopmental assessment was carried out at 2 years of age using the Bayley Scales of Infant Development 2nd Edition by a developmental psychologist. Eleven (68.8%) infants completed the 2-year follow-up. Results: The median mental developmental index (MDI) and physical developmental index scores were 85 (interquartile range, IQR = 27) and 87 (IQR = 33), respectively. Two infants (18.2%) had developmental disability (MDI scores <70). Conclusion: Survivors of PPHN are at risk of developmental disabilities. Early intervention programme and long-term follow-up should be integrated in the management of these infants. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|